Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment

Sadna Budhu1*, David Schaer2, Yongbiao Li3, Alan Houghton1, Samuel Silverstein4, Taha Merghoub1, Jedd D Wolchok1

From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014

Regulatory T cells (Treg) play a role in suppression of anti-melanoma immunity; however, the exact mechanism is poorly understood. Through intravital two photon microscopy, we found that tumor-specific Pmel-1 effectors engage in cell-cell interactions with tumor resident Tregs. To determine if contact between Tregs and Teff hinders killing of tumor cells in vivo, we utilized ex-vivo three-dimensional collagen-fibrin gel cultures of B16 melanoma cells. Collagen-fibrin gel cultures recapitulated the in vivo suppression, rendering the dissociated tumor resistant to killing by in vitro activated antigen specific T cells. In vivo depletion of Tregs in Foxp3-DTR mice prior to tumor excision reversed the suppression. In vivo modulation of Tregs by GITR ligation had a similar effect, reducing the number of intra-tumor Tregs leading to ex-vivo tumor killing. Using neutralizing antibodies, we found that blocking TGF-β reversed the suppression. In addition, soluble factors from collagen-fibrin gel tumors do not inhibit killing suggesting that suppression is contact or proximity dependent. The CD8 T cells recovered from these gels exhibit a decrease in Granzyme B expression and an increase in expression of T cell exhaustion marker PD-1. These findings support the conclusion that intra-tumor contact with Tregs during the effector phase of the immune response is responsible for inhibiting anti-melanoma immunity in a TGF-β dependent manner shedding light into novel ways to inhibit intratumoral Tregs.

This study was supported by Swim Across America; NIH grants R01CA56821, P01CA33049, and P01CA59350 (to J.W. and A.H.); D.S. and S.B. received support from the NIH/NCI Immunology Training GrantT32 CA09149-30.

Authors’ details
1Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2Cancer Immunobiology, ImClone Systems, New York, NY, USA. 3Research Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4Physiology and Cellular Biophysics, Columbia University Medical Center, New York, NY, USA.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P192

Cite this article as: Budhu et al.: Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment. Journal for Immunotherapy of Cancer 2014 2(Suppl 3): P192.